MLYS FINANCIAL STATEMENTS

Mineralys Therapeutics, Inc. Common Stock — balance sheet, income statement and cash flow trends

MLYSMineralys Therapeutics, Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue0 $-100.0%

Gross Profit-50 K $—

Operating Income-171.5 M $—

EBITDA-151.7 M $—

Net Income-151.8 M $—

Peer Comparison· Biotechnology

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
MLYS	-100.0%	—	—	—
TLX	56.3%	50.8%	3.0%	-0.9%
MSB	410.4%	-32.0%	-76.6%	-115.3%
CSL	4.8%	48.6%	32.8%	9.2%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
MLYS	-100.0%	—	—	—
SRPT	-2.2%	62.4%	5.7%	3.0%
BHVN	-100.0%	—	—	—
AGIO	78.3%	82.1%	-633.4%	-639.8%
KOD	-100.0%	—	—	—
VCEL	22.4%	74.8%	12.1%	7.3%
Industry median	5.1%	84.0%	-105.8%	-125.7%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Equity638.1 M $98%
Current Liabilities14.7 M $2%

Key Figures

YoY change

Total Assets652.9 M $+83.9%

Total Liabilities14.7 M $+10.0%

Total Equity638.1 M $+86.8%

Cash & ST Investments646.1 M $+88.3%

Total Debt——

Net Debt-112.8 M $—

Peer Comparison· Biotechnology

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
MLYS	44.33	—	—	97.7%
TLX	1.43	112.3%	13.13	35.1%
MSB	—	—	—	—
CSL	2.57	67.4%	2.22	49.2%
Industry median	5.90	10.9%	1.15	70.0%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
MLYS	44.33	—	—	97.7%
SRPT	4.63	68.9%	3.07	47.3%
BHVN	7.41	221.0%	0.10	27.8%
AGIO	14.19	3.2%	1.68	93.6%
KOD	3.54	139.2%	0.07	36.6%
VCEL	5.18	26.5%	-1.44	73.4%
Industry median	5.90	10.9%	1.15	70.0%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-136.4 M $—

Capital Expenditures15 K $-59.5%

Free Cash Flow-136.4 M $—

Dividends Paid——

Peer Comparison· Biotechnology

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
MLYS	—	—	—	89.9%
TLX	-2.2%	-6.3%	4.1%	243.1%
MSB	-87.7%	-90.0%	2.3%	76.1%
CSL	24.0%	20.3%	3.7%	261.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
MLYS	—	—	—	89.9%
SRPT	8.0%	4.9%	3.2%	269.4%
BHVN	—	—	—	91.7%
AGIO	-576.0%	-582.5%	6.5%	90.0%
KOD	—	—	—	63.7%
VCEL	21.1%	19.8%	11.1%	287.5%
Industry median	-88.0%	-90.9%	1.9%	81.5%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on MLYS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.